Hillary Clinton is urging federal regulators to go after an embattled pharma CEO who raised the price of a decades-old medication by 5,000 percent.
The Democratic front-runner wrote to the Food and Drug Administration and the Federal Trade Commission about the anti-parasite drug Daraprim, according to Reuters. The price of the generic drug rose from $13.50 to $750 after Turing Pharmaceuticals, led by 32-year-old former hedge fund manager Martin Shkreli, acquired the drug in August.
Clinton said in the letters that Turing has not lowered the price of Daraprim, despite promises last month from Shkreli to do so, Reuters said. She wants the FDA to expedite any pending reviews of Daraprim generics so that they reach the market soon, and called for changes in law to ensure similar situations don’t happen again.
A big reason that Shkreli has been able to raise the price of Daraprim is that there is no other generic competition. The drug has been around for decades and only has a few thousand prescriptions. But if generic alternatives reach the market, they can sell Daraprim at a lower price.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Musk’s X Requests Brazil Supreme Court to Resume Service After Shutdown
Sep 26, 2024 by
CPI
Visa Acquires AI Firm Featurespace to Enhance Fraud Prevention
Sep 26, 2024 by
CPI
Visa Gears Up for Legal Fight with DOJ Over Debit Card Monopoly Allegations
Sep 26, 2024 by
CPI
UFC Fighters’ Lawsuit Settlement Resurfaces with $375 Million Offer
Sep 26, 2024 by
CPI
Ex-Amazon Seller Appario Files Lawsuit to Dismiss Antitrust Allegations
Sep 26, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
Francisco Javier Núñez Melgoza
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
Julio Garcia
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
Alejandra Palacios Prieto
The Cost of Making COFECE Disappear
Sep 3, 2024 by
Mateo Fernández